Our Approach

We are advancing cancer care by developing next-generation therapies to address treatment resistance.

Leveraging our team’s deep expertise in developing targeted cancer therapies, Theseus is addressing the challenge of drug resistance by developing the next generation of pan-variant tyrosine kinase inhibitors (TKIs).

At Theseus, we believe truly transformative, targeted cancer therapeutics must simultaneously inhibit all cancer-causing and resistance mutations. We are focused on outsmarting cancer resistance by developing pan-variant therapies that inhibit cancer cell function and improve potential treatment outcomes.

Our drug development approach has three pillars:

Validated Molecular Targets

1

Validated Molecular Targets

Pursuing well-understood targets where mutations commonly emerge allows us to minimize the biological risk associated with drug development.

Unique Discovery Platform

2

Unique Discovery Platform

We use an iterative process that combines a distributed chemical structure to optimize “pan-ness” against known mutations with our novel Predictive Resistance Assay (PRA) that can accurately predict clinical outcomes of TKIs against anticipated variants.

Biomarker-Guided Design

3

Biomarker-Guided Design

We employ biomarkers early on in clinical development, allowing us to assess activity efficiently against individual mutant variants and accelerate programs accordingly to reach patients faster.

Cancer-causing and resistance mutations limit the efficacy of existing targeted cancer therapies by rendering tumor cells unresponsive to drugs. Our next-generation, pan-variant TKIs may successfully address the challenge of resistance.

We are developing a pipeline of TKIs designed to inhibit all major cancer-causing and drug resistance mutations in tyrosine kinase targets.

VIEW OUR PIPELINE